Ken Griffin Gain Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,700 shares of GANX stock, worth $15,561. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,700Holding current value
$15,561% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding GANX
# of Institutions
27Shares Held
2.77MCall Options Held
0Put Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.61 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.55 Million0.06% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$730,0590.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA177KShares$483,4140.0% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny158KShares$431,7630.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $32.4M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...